Dr. Nicholas Short
Claim this profileM D Anderson Cancer Center
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
11 reported clinical trials
16 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
FLT3 positive
NPM1 positive
CEBPA positive
2Acute Myeloid Leukemia
FLT3 positive
NPM1 positive
CEBPA positive
Affiliated Hospitals
Clinical Trials Nicholas Short is currently running
Gilteritinib + Momelotinib
for Acute Myeloid Leukemia
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Recruiting1 award Phase 1 & 27 criteria
Azacitidine + Venetoclax + Gilteritinib
for Leukemia
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment (refractory). Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine, venetoclax, and gilteritinib may work better compared to azacitidine and venetoclax alone in treating patients with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndrome/myeloproliferative neoplasm.
Recruiting3 awards Phase 1 & 210 criteria
More about Nicholas Short
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Nicholas Short has experience with
- Venetoclax
- Azacitidine
- Gilteritinib
- Decitabine
- Pevonedistat
- Ponatinib
Breakdown of trials Nicholas Short has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Leukemia
Chronic Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas Short specialize in?
Nicholas Short focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved FLT3 positive patients, or patients who are NPM1 positive.
Is Nicholas Short currently recruiting for clinical trials?
Yes, Nicholas Short is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Nicholas Short has studied deeply?
Yes, Nicholas Short has studied treatments such as Venetoclax, Azacitidine, Gilteritinib.
What is the best way to schedule an appointment with Nicholas Short?
Apply for one of the trials that Nicholas Short is conducting.
What is the office address of Nicholas Short?
The office of Nicholas Short is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.